Clinical Trials Directory

Trials / Unknown

UnknownNCT02484872

Has Inflammation a Significant Implication in Lung Cancer Evolution?

L'Inflammation A-t-elle Une Implication Significative Dans l'évolution du Cancer Bronchique?

Status
Unknown
Phase
Study type
Observational
Enrollment
400 (estimated)
Sponsor
European Lung Cancer Working Party · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

Detailed description

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.

Conditions

Timeline

Start date
2015-05-01
Primary completion
2022-12-01
Completion
2023-12-01
First posted
2015-06-30
Last updated
2021-08-23

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT02484872. Inclusion in this directory is not an endorsement.